Literature DB >> 29655286

Reduced expression of oestrogen receptor-β is associated with tumour invasion and metastasis in oestrogen receptor-α-negative human papillary thyroid carcinoma.

Wen-Wu Dong1, Jian Li2, Jing Li3, Ping Zhang1, Zhi-Hong Wang1, Wei Sun1, Hao Zhang1.   

Abstract

Oestrogens play an important role in the development and progression of papillary thyroid carcinoma (PTC) through oestrogen receptor (ER)-α and -β, which may exert different or even opposing actions in PTC. The roles of ERβ in ERα-negative PTC are still not clear. This study investigated the expression dynamics of ERβ1 (wild-type ERβ) and its clinical significance in female ERα-negative PTC patients. ERβ1 expression was detected in thyroid tissues of 136 female patients diagnosed with PTC. The relationships between ERβ1 expression and clinicopathological/biological factors were also analysed in female ERα-negative PTC patients. The total score for ERβ1 was significantly lower in female ERα-negative PTC patients with LNM or ETE when compared to those without LNM or ETE (Z = -2.923, P = 0.003 and Z = -3.441, P = 0.001). Accordingly, the total score for ERβ1 was significantly higher in ERα-negative PTC patients expressing E-cadherin compared to patients negative for E-cadherin expression (Z = -2.636, P = 0.008). The total score was lower in ERα-negative PTC patients positive for VEGF expression compared to those negative for VEGF expression (Z = -1.914, P = 0.056). This preliminary study indicates that reduced expression of ERβ1 in female ERα-negative PTC patients is associated with greater progression of the disease. This may provide insights into the underlying molecular mechanisms of ERβ1 and could help design targeted approaches for treating or even preventing this disease.
© 2018 The Authors. International Journal of Experimental Pathology © 2018 International Journal of Experimental Pathology.

Entities:  

Keywords:  immunohistochemistry; oestrogen receptor-α; oestrogen receptor-β; papillary thyroid cancer

Mesh:

Substances:

Year:  2018        PMID: 29655286      PMCID: PMC5917391          DOI: 10.1111/iep.12266

Source DB:  PubMed          Journal:  Int J Exp Pathol        ISSN: 0959-9673            Impact factor:   1.925


  48 in total

1.  Estrogen receptor (ER)-beta, but not ER-alpha, is present in thyroid vessels: immunohistochemical evaluations in multinodular goiter and papillary thyroid carcinoma.

Authors:  Graziano Ceresini; Simonetta Morganti; Virna Graiani; Maria Saccani; Bruna Milli; Elisa Usberti; Giorgio Valenti; Gian Paolo Ceda; Luigi Corcione
Journal:  Thyroid       Date:  2006-12       Impact factor: 6.568

2.  Trends in Thyroid Cancer Incidence and Mortality in the United States, 1974-2013.

Authors:  Hyeyeun Lim; Susan S Devesa; Julie A Sosa; David Check; Cari M Kitahara
Journal:  JAMA       Date:  2017-04-04       Impact factor: 56.272

3.  Immunohistochemical Expression of Estrogen Receptor-α and Progesterone Receptor in Patients with Papillary Thyroid Cancer.

Authors:  Giacomo Sturniolo; Carles Zafon; Mariacarla Moleti; Josep Castellví; Francesco Vermiglio; Jordi Mesa
Journal:  Eur Thyroid J       Date:  2016-11-24

4.  Estrogen receptor beta expression is associated with tamoxifen response in ERalpha-negative breast carcinoma.

Authors:  Sofia K Gruvberger-Saal; Pär-Ola Bendahl; Lao H Saal; Mervi Laakso; Cecilia Hegardt; Patrik Edén; Carsten Peterson; Per Malmström; Jorma Isola; Ake Borg; Mårten Fernö
Journal:  Clin Cancer Res       Date:  2007-04-01       Impact factor: 12.531

5.  Upregulation of the ESR1 Gene and ESR Ratio (ESR1/ESR2) is Associated with a Worse Prognosis in Papillary Thyroid Carcinoma: The Impact of the Estrogen Receptor α/β Expression on Clinical Outcomes in Papillary Thyroid Carcinoma Patients.

Authors:  Jin Wook Yi; Su-Jin Kim; Jong Kyu Kim; Chan Yong Seong; Hyeong Won Yu; Young Jun Chai; June Young Choi; Kyu Eun Lee
Journal:  Ann Surg Oncol       Date:  2017-01-25       Impact factor: 5.344

Review 6.  Prognosis and growth activity depend on patient age in clinical and subclinical papillary thyroid carcinoma.

Authors:  Yasuhiro Ito; Akira Miyauchi; Kaoru Kobayashi; Akihiro Miya
Journal:  Endocr J       Date:  2013-12-09       Impact factor: 2.349

7.  Clinical importance of estrogen receptor-beta evaluation in breast cancer patients treated with adjuvant tamoxifen therapy.

Authors:  Naoko Honma; Rie Horii; Takuji Iwase; Shigehira Saji; Mamoun Younes; Kaiyo Takubo; Masaaki Matsuura; Yoshinori Ito; Futoshi Akiyama; Goi Sakamoto
Journal:  J Clin Oncol       Date:  2008-08-01       Impact factor: 44.544

8.  Clinical significance of E-cadherin as a prognostic marker in thyroid carcinomas.

Authors:  G F Scheumman; C Hoang-Vu; Y Cetin; O Gimm; J Behrends; R von Wasielewski; A Georgii; W Birchmeier; A von Zur Mühlen; H Dralle
Journal:  J Clin Endocrinol Metab       Date:  1995-07       Impact factor: 5.958

9.  Differential expression patterns of estrogen receptor (ER)-β splice variants between papillary thyroid cancer and nodular thyroid goiter.

Authors:  Wenwu Dong; Jing Li; Yanhong Huang; Hao Zhang; Zhongyan Shan; Weiping Teng
Journal:  Med Sci Monit       Date:  2012-09

10.  Estrogen Induces Metastatic Potential of Papillary Thyroid Cancer Cells through Estrogen Receptor α and β.

Authors:  Wenwu Dong; Hao Zhang; Jing Li; Haixia Guan; Liang He; Zhihong Wang; Zhongyan Shan; Weiping Teng
Journal:  Int J Endocrinol       Date:  2013-10-10       Impact factor: 3.257

View more
  6 in total

1.  Orchestrated expression of vasculogenic mimicry and laminin-5γ2 is an independent prognostic marker in oral squamous cell carcinoma.

Authors:  Depanwita Saha; Debarpan Mitra; Neyaz Alam; Sagar Sen; Saunak Mitra Mustafi; Syamsundar Mandal; Biswanath Majumder; Nabendu Murmu
Journal:  Int J Exp Pathol       Date:  2022-02-16       Impact factor: 1.925

Review 2.  Estrogen Receptor Beta: The Promising Biomarker and Potential Target in Metastases.

Authors:  Ana Božović; Vesna Mandušić; Lidija Todorović; Milena Krajnović
Journal:  Int J Mol Sci       Date:  2021-02-06       Impact factor: 5.923

Review 3.  Can We Predict Differentiated Thyroid Cancer Behavior? Role of Genetic and Molecular Markers.

Authors:  Rita Niciporuka; Jurijs Nazarovs; Arturs Ozolins; Zenons Narbuts; Edvins Miklasevics; Janis Gardovskis
Journal:  Medicina (Kaunas)       Date:  2021-10-19       Impact factor: 2.948

Review 4.  Sex Bias in Differentiated Thyroid Cancer.

Authors:  Valentine Suteau; Mathilde Munier; Claire Briet; Patrice Rodien
Journal:  Int J Mol Sci       Date:  2021-11-30       Impact factor: 5.923

Review 5.  Estrogen Receptor Beta (ERβ): A Ligand Activated Tumor Suppressor.

Authors:  Rahul Mal; Alexa Magner; Joel David; Jharna Datta; Meghna Vallabhaneni; Mahmoud Kassem; Jasmine Manouchehri; Natalie Willingham; Daniel Stover; Jeffery Vandeusen; Sagar Sardesai; Nicole Williams; Robert Wesolowski; Maryam Lustberg; Ramesh K Ganju; Bhuvaneswari Ramaswamy; Mathew A Cherian
Journal:  Front Oncol       Date:  2020-10-23       Impact factor: 6.244

6.  Expression of Estrogen and Progesterone Receptors in Papillary Thyroid Carcinoma in Korea.

Authors:  Hwa Young Ahn; Ra-Yeong Song; Hye Shin Ahn; Hee Sung Kim
Journal:  Cancer Res Treat       Date:  2021-02-10       Impact factor: 4.679

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.